Lymphoblastic Lymphoma is an aggressive form of non-Hodgkin lymphoma, however it is relatively very rare form affecting an estimated 2% patients of all non-Hodgkin lymphoma patients. Lymphoblastic Lymphoma mainly affects teenagers or adults in their early 20’s, and occurs more frequently in males than in females. Lymphoblastic Lymphoma arises most commonly from T-cells / t-lymphocytes, and is predominantly a lymph node-based disease, primarily affecting the lymphatic system. The clinical distinction of the diseases lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ACL), have been varying according to different institutions and studies. But recently the World Health Organization (WHO) stated that the characteristics of Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia are similar at all levels genetically, morphologically and phenotypically as well, and hence has unified these diseases, as the precursors of T-cells / B-cells lymphoblastic lymphoma/leukemia.
The lymphoblastic lymphoma involves both T-lymphocytes and B-lymphocytes, of which 84-90% cases of lymphoblastic lymphoma involve T-lymphocytes. Chemotherapy is the preferred choice and first line treatment in cases of lymphoblastic lymphoma, where the regimen is followed for the treatment and includes induction chemotherapy, consolidation chemotherapy and continuing chemotherapy. Other treatments include radiotherapy which might be given in the brain or spine if the lymphoma cells are present or in other areas, stem cell transplantation, and steroids. Though lymphoblastic lymphoma is a rare and aggressive form of non-Hodgkin lymphoma, it can be cured with 80-90% survival rates in children with intensive therapy for early stages (I & II), while 80% survival rates in more advanced stages of lymphoblastic lymphoma (Stage III & IV).
Rising incidences combined with increasing prevalence of cancer around the world, has been the prime factor which is expected to drive the global lymphoblastic lymphoma market growth during the forecast period of 2016-2024. Also, increasing prevalence of genetic diseases, and technological advancements in the fields of diagnostics is expected to drive the growth of the global lymphoblastic lymphoma. According to American Cancer Society, as of January 1, 2016, there were an estimated 686,390 non-Hodgkin lymphoma cancer survivors in the U.S., out of which around 13,727 patients were of lymphoblastic lymphoma survivors. Surveillance studies of the American Cancer Society also indicate that by 2026, the total number of all types of cancer survivors is expected to reach 20.3 Mn patients out of which people suffering from non-Hodgkin lymphoma is expected to reach 925,150. This increasing incidence and prevalence rate is expected to drive the global lymphoblastic leukemia market growth during 2016-2024.
Region wise, the global lymphoblastic leukemia market is classified into regions namely, North America, Latin America, Europe, Asia-Pacific, Middle East and Africa. North America dominated the global lymphoblastic lymphoma market in 2015, due to increasing prevalence of cancer especially non-Hodgkin Lymphoma, along with advanced diagnostic instruments and technologies, increasing healthcare expenditure, and rising demand from patients for better healthcare facilities, followed by Europe region owing to increasing focus on targeted drugs for diseases, and rising prevalence of cancer. Asia Pacific is expected to register highest CAGR in the global lymphoblastic lymphoma market during the forecast period of 2016-2024. Rising genetic diseases, and increasing incidences of non-Hodgkin Lymphoma among the Asia Pacific countries such as China, and India, have been the prime factors expected to drive the growth of this region in the global lymphoblastic lymphoma market during 2016-2024.
Some of the key players in this market are Novartis AG, Sanofi SA, Pfizer Inc., Bristol-Myers Squibb Company, Jazz Pharmaceuticals plc, AstraZeneca, Eisai Inc., Amgen Inc. and BioCryst Pharmaceuticals, Inc. Key players in the research and development are National Cancer Institute, The University of Texas M. D. Anderson Cancer Center, Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center , St. Jude Children\'s Research Hospital, Inc., Johann Wolfgang Goethe University Hospitals and others.